Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is March 25, 2025, covering a share repurchase executed on March 24, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial performance metrics such as revenue or profit.
- Shares Purchased: 587,100 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,482.00 GBp; highest price paid was 1,516.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,490.87 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Treasury Shares Held: 183,107,390 ordinary shares (post-transaction).
- Shares in Issue: 4,132,107,456 ordinary shares (excluding Treasury shares).
- Total Voting Rights: 4,132,107,456.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the commencement of the current buyback agreement on February 24, 2025, GSK has purchased an aggregate of 14,037,087 ordinary shares. The March 24 transaction represents the latest execution within this programme. The total number of voting rights remains 4,132,107,456, which serves as the denominator for shareholder notification calculations under FCA rules.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. These risks are referenced as being described on pages 277 to 285 of the GSK 2024 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the total cumulative spend on the buyback programme since February 24, 2025, by aggregating daily transaction data.
- Confirm the remaining authorization limit for the current buyback programme to assess future repurchase capacity.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for detailed risk factors referenced in the filing.
- Monitor subsequent 6-K filings for updates on the total number of treasury shares held and shares in issue.